RIOT vs. VIVO, OSTK, OXFD, AWH, ALLY, BSAC, WF, SOFI, OMF, and CADE
Should you be buying Riot Platforms stock or one of its competitors? The main competitors of Riot Platforms include Meridian Bioscience (VIVO), Overstock.com (OSTK), Oxford Immunotec Global (OXFD), Aspira Women's Health (AWH), Ally Financial (ALLY), Banco Santander-Chile (BSAC), Woori Financial Group (WF), SoFi Technologies (SOFI), OneMain (OMF), and Cadence Bank (CADE).
Riot Platforms (NASDAQ:RIOT) and Meridian Bioscience (NASDAQ:VIVO) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.
In the previous week, Riot Platforms had 10 more articles in the media than Meridian Bioscience. MarketBeat recorded 11 mentions for Riot Platforms and 1 mentions for Meridian Bioscience. Meridian Bioscience's average media sentiment score of 0.00 beat Riot Platforms' score of -0.18 indicating that Meridian Bioscience is being referred to more favorably in the news media.
40.3% of Riot Platforms shares are held by institutional investors. Comparatively, 89.7% of Meridian Bioscience shares are held by institutional investors. 4.4% of Riot Platforms shares are held by insiders. Comparatively, 2.3% of Meridian Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Riot Platforms has a net margin of 76.02% compared to Meridian Bioscience's net margin of 12.70%. Meridian Bioscience's return on equity of 16.74% beat Riot Platforms' return on equity.
Riot Platforms currently has a consensus price target of $16.91, suggesting a potential upside of 50.98%. Given Riot Platforms' higher probable upside, equities analysts plainly believe Riot Platforms is more favorable than Meridian Bioscience.
Riot Platforms received 191 more outperform votes than Meridian Bioscience when rated by MarketBeat users. Likewise, 67.78% of users gave Riot Platforms an outperform vote while only 49.84% of users gave Meridian Bioscience an outperform vote.
Riot Platforms has a beta of 4.15, suggesting that its stock price is 315% more volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.
Meridian Bioscience has higher revenue and earnings than Riot Platforms. Riot Platforms is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Riot Platforms beats Meridian Bioscience on 9 of the 17 factors compared between the two stocks.
Get Riot Platforms News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIOT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RIOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Riot Platforms Competitors List
Related Companies and Tools
Free RIOT Stock Alerts